All In Biotech

Drug Trial Radar · NCT04751487

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,234 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,234

Actual

Start

Feb 12, 2021

Primary completion

Apr 21, 2025

Study completion Aug 28, 2025

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Feb 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: Primary population (former smokers cohort): \- Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Primary population (former smokers cohort): * Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on occurrence of acute exacerbation of COPD (AECOPD) in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on severe AECOPD in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on corticosteroid-treated AECOPD in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on respiratory symptoms in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on Forced Expiratory Volume in 1 second (FEV1) slope in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on health-related quality of life (HRQoL) as assessed by St. George's Respiratory Questionnaire (SGRQ) in former smokers with moderate-to-severe COPD * Evaluate the safety and tolerability of itepekimab in former smokers with moderate-to-severe COPD * Evaluate the pharmacokinetic (PK) profile of itepekimab in former smokers with moderate-to-severe COPD * Evaluate immunogenicity to itepekimab in former smokers with moderate-to-severe COPD Secondary population (current smokers cohort) * Estimate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate or severe COPD exacerbations in current smokers with moderate-to-severe COPD * Estimate the efficacy of itepekimab compared with placebo on pulmonary function in current smokers with moderate-to-severe COPD * Estimate the safety and tolerability of itepekimab in current smokers with moderate-to-severe COPD * Estimate the PK profile of itepekimab in current smokers with moderate to severe COPD * Estimate immunogenicity to itepekimab in current smokers with moderate-to-severe COPD

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Itepekimab SAR440340Drug

    Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous

  • PlaceboDrug

    Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Former Smoker Cohort: Annualized Rate of Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) Events Over the 52-Week Placebo-Controlled Treatment PeriodTime frame: Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Weeks 24 to 52 for additional randomized participants

Locations

238 sites in 29 countries. Site status is shown where the registry gives one.

  • Synexus Phoenix Central (Central Phoenix Medical Clinic)- Site Number : 8400333

    Phoenix, Arizona

  • UCSF Fresno - Site Number : 8400030

    Fresno, California

  • Palmtree Clinical Research Site Number : 8400184

    Palm Springs, California

  • Allianz Research Institute Colorado Site Number : 8400061

    Denver, Colorado

  • Helix Biomedics, LLC - Site Number : 8400049

    Boynton Beach, Florida

  • Innovative Research of West Florida, Inc- Site Number : 8400041

    Clearwater, Florida

  • Beautiful Minds Clinical Research Center Site Number : 8400352

    Cutler Bay, Florida

  • Omega Research - Site Number : 8400031

    DeBary, Florida

  • Sciences Connections, LLC Site Number : 8400045

    Doral, Florida

  • North Florida/South Georgia Veterans Health System Site Number : 8400176

    Gainesville, Florida

  • Finlay Medical Research- Site Number : 8400011

    Greenacres City, Florida

  • Direct Helpers Medical Center Inc- Site Number : 8400065

    Hialeah, Florida

  • Multi-Specialty Research Associates, Inc- Site Number : 8400044

    Lake City, Florida

  • Advanced Pulmonary Research Institute Site Number : 8400018

    Loxahatchee Groves, Florida

  • Columbus Clinical Services- Site Number : 8400054

    Miami, Florida

  • Finlay Medical Research Site Number : 8400007

    Miami, Florida

  • MCR Research Site Number : 8400425

    Miami, Florida

  • Y and L Advance Health Care, Inc D/B/A Elite Clinical Res- Site Number : 8400009

    Miami, Florida

  • My Community Research Center Site Number : 8400060

    Miami, Florida

  • Phoenix Medical Research- Site Number : 8400019

    Miami, Florida

  • Renstar Medical Research- Site Number : 8400015

    Ocala, Florida

  • Central Florida Pulmonary Group, PA- Site Number : 8400192

    Orlando, Florida

  • Oviedo Medical Research Site Number : 8400026

    Oviedo, Florida

  • Innovation Medical Research Center- Site Number : 8400067

    Palmetto Bay, Florida

  • Pines Care Research Center LLC- Site Number : 8400056

    Pembroke Pines, Florida

  • Sarasota Memorial Health Care System Clinical ResearchCenter- Site Number : 8400178

    Sarasota, Florida

  • Genesis Clinical Research, LLC Site Number : 8400182

    Tampa, Florida

  • Clinical Research of West Florida, Inc- Site Number : 8400008

    Tampa, Florida

  • Medster Research, LLC Site Number : 8400051

    Valdosta, Georgia

  • North Georgia Clinical Research Site Number : 8400013

    Woodstock, Georgia

  • Care Access Fairview Heights Site Number : 8400033

    Fairview Heights, Illinois

  • Captain James A. Lovell Federal Health Care Center Site Number : 8400032

    North Chicago, Illinois

  • Illinois Lung Institute- Site Number : 8400024

    Peoria, Illinois

  • The Iowa Clinic Site Number : 8400034

    West Des Moines, Iowa

  • Cotton O'Neil Garfield- Site Number : 8400063

    Topeka, Kansas

  • Pulmonary & Critical Care Site Number : 8400047

    Shreveport, Louisiana

  • Johns Hopkins Asthma and Allergy Center- Site Number : 8400055

    Baltimore, Maryland

  • Care Access Site Number : 8400276

    Boston, Massachusetts

  • Care Access Site Number : 8400281

    Boston, Massachusetts

  • Revive Research Institute Site Number : 8400186

    Lathrup Village, Michigan

Showing 40 of 238 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.